Does RUXOLITINIB Cause Therapeutic product effect delayed? 33 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 33 reports of Therapeutic product effect delayed have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.1% of all adverse event reports for RUXOLITINIB.
33
Reports of Therapeutic product effect delayed with RUXOLITINIB
0.1%
of all RUXOLITINIB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Therapeutic product effect delayed From RUXOLITINIB?
Of the 33 reports, 2 (6.1%) required hospitalization.
Is Therapeutic product effect delayed Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 33 reports have been filed with the FAERS database.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Therapeutic product effect delayed?
ADALIMUMAB (244)
TOFACITINIB (178)
CARBIDOPA\LEVODOPA (168)
SECUKINUMAB (162)
POLYETHYLENE GLYCOL 3350 (125)
RIMEGEPANT (120)
TASIMELTEON (93)
DUPILUMAB (90)
IBUPROFEN (88)
DICLOFENAC (85)
Which RUXOLITINIB Alternatives Have Lower Therapeutic product effect delayed Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE